+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2020

  • PDF Icon

    Drug Pipelines

  • 310 Pages
  • October 2020
  • Region: Global
  • Global Markets Direct
  • ID: 5189093
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Radiation Toxicity - Pipeline Review, H2 2020, provides an overview of the Radiation Toxicity (Toxicology) pipeline landscape.

Radiation Toxicity (also known as radiation sickness) is an acute illness caused by irradiation of the entire body by a high dose of penetrating radiation in a very short period of time (usually a matter of minutes). The major cause of this syndrome is depletion of immature parenchymal stem cells in specific tissues. Symptoms include bleeding from the nose, mouth, gums, and rectum, bloody stool, bruising, confusion, dehydration, diarrhea, fainting and fatigue.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Radiation Toxicity - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Radiation Toxicity (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Radiation Toxicity (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 9, 7, 1, 49, 6 and 1 respectively. Similarly, the Universities portfolio in Preclinical, Discovery and Unknown stages comprises 6, 1 and 1 molecules, respectively.

Radiation Toxicity (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Radiation Toxicity (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Radiation Toxicity (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Radiation Toxicity (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Radiation Toxicity (Toxicology)

Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Radiation Toxicity (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Radiation Toxicity (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Radiation Toxicity - Overview
  • Radiation Toxicity - Therapeutics Development
  • Radiation Toxicity - Therapeutics Assessment
  • Radiation Toxicity - Companies Involved in Therapeutics Development
  • Radiation Toxicity - Drug Profiles
  • Radiation Toxicity - Dormant Projects
  • Radiation Toxicity - Discontinued Products
  • Radiation Toxicity - Product Development Milestones
  • Appendix

List of Tables
  • Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by 21st Century Therapeutics Inc, H2 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by 9 Meters Biopharma Inc, H2 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Advanced Innovative Partners Inc, H2 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Advenchen Laboratories LLC, H2 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Amryt Pharma Plc, H2 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Angion Biomedica Corp, H2 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Aqualung Therapeutics Corp, H2 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Atox Bio Ltd, H2 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by BCN Biosciences LLC, H2 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by BioCurity Pharmaceuticals Inc, H2 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by BioIncept LLC, H2 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Bolder Biotechnology Inc, H2 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cellphire Inc, H2 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Ceramedix Holding LLC, H2 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Ceramide Therapeutics LLC, H2 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Chrysalis BioTherapeutics Inc, H2 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cleveland BioLabs Inc, H2 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Consegna Pharma Inc, H2 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Creative Medical Technology Holdings Inc, H2 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Daiichi Sankyo Co Ltd, H2 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Eagle Pharmaceuticals Inc, H2 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H2 2020
  • Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products, H2 2020

List of Figures
  • Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Top 10 Routes of Administration, H2 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Top 10 Molecule Types, H2 2020

Companies Mentioned

A selection of companies mentioned in this report includes:

  • 21st Century Therapeutics Inc
  • 9 Meters Biopharma Inc
  • Advanced Innovative Partners Inc
  • Advenchen Laboratories LLC
  • Amryt Pharma Plc
  • Angion Biomedica Corp
  • Aqualung Therapeutics Corp
  • Atox Bio Ltd
  • BCN Biosciences LLC
  • BioCurity Pharmaceuticals Inc
  • BioIncept LLC
  • Bolder Biotechnology Inc
  • Cellphire Inc
  • Ceramedix Holding LLC
  • Ceramide Therapeutics LLC
  • Chrysalis BioTherapeutics Inc
  • Cleveland BioLabs Inc
  • Consegna Pharma Inc
  • Creative Medical Technology Holdings Inc
  • Daiichi Sankyo Co Ltd
  • Eagle Pharmaceuticals Inc
  • Enzychem Lifesciences Corp
  • EpicentRx Inc
  • Exponential Biotherapies Inc
  • Extend Biosciences Inc
  • Fibreu Ltd
  • FirstString Research Inc
  • Foresee Pharmaceuticals Co Ltd
  • Genexine Inc
  • GNI Group Ltd
  • Humanetics Corp
  • Inflammatory Response Research Inc
  • iNtRON Biotechnology Inc
  • Jay Pharma Inc
  • KannaLife Sciences Inc
  • Luxena Pharmaceuticals Inc
  • Matrix Biomed Inc
  • Meabco AS
  • Medesis Pharma SA
  • Neumedicines Inc
  • New Amsterdam Sciences Inc
  • Nohla Therapeutics Inc
  • Novartis AG
  • Noveome Biotherapeutics Inc
  • Onconova Therapeutics Inc
  • Original BioMedicals Co Ltd
  • P2D Inc
  • PharmaIN Corp
  • Phoenicia Biosciences Inc
  • Pluristem Therapeutics Inc
  • Regeneus Ltd
  • RepoCeuticals ApS
  • RxBio Inc
  • Soligenix Inc
  • Sunny Pharmtech Inc
  • Synedgen Inc
  • Therapeutic Systems Research Laboratories Inc
  • TheraSource LLC
  • Tonix Pharmaceuticals Holding Corp
  • Valenta Pharm
  • Worphmed Srl